ADCS – The Dawn Of A New Era?

The technology behind antibody-drug conjugates (ADCs) has been around for many years, but key learnings in the clinic have furthered our understanding of how to improve clinical and patient outcomes.  In this article, Penelope Drake and David Rabuka of Catalent Biologics discuss the history of ADC clinical trials and approvals and the trends governing current and future ADC development.

Click here to view article.